Long-listed products (LLPs) in Japan will be subject to a new health coverage scheme starting this October. This is expected…
HOME > BUSINESS
BUSINESS
- Map Software Used to Reorganize MRs’ Marketing Territories Boosts Operating Efficiency at Pfizer Japan
March 7, 2014
- Five Generic Makers See Various Price Reduction Rates under FY2014 NHI Revision
March 6, 2014
- New Price Cuts for Long-Listed Drugs to Pummel MTPC, Astellas: Jiho Tally
March 6, 2014
- Santen Licenses Anti-Endoglin Antibodies from TRACON to Develop Novel Treatments for Retinal Diseases
March 6, 2014
- Samsca Tops January “Mind Share” Ranking in HP Market
March 5, 2014
- Eylea Filed for Diabetic Macular Edema in Japan: Bayer HealthCare
March 5, 2014
- Takeda Extended 3.7 Billion Yen in CASE-J-Linked Grants to Kyoto Univ., 2 Entities; “No COI” Says Pres. Hasegawa
March 4, 2014
- Takeda Apologizes for Violating Promotion Code, Inappropriate Expressions in Ads
March 4, 2014
- DSP Transfers Marketing Rights for Inteban, Catlep, and Drenison to Teikoku Seiyaku
March 4, 2014
- Astellas Secures Exclusive Rights for Isavuconazole in US, Canada
March 4, 2014
- Dnavec, NCGM, Nippon Zenyaku to Codevelop Drug Discovery Tool for Anti-Obesity Treatment
March 3, 2014
- Takeda Files NDA for Promising Acid-Related Disease Drug in Japan
March 3, 2014
- Novartis Files for Approval of Exforge OD Tablets
March 3, 2014
- Takeda’s Next Leader Weber to Take Up COO Role on April 1
March 3, 2014
- Mizuho Projects 5% Upswing for FY2014 Operating Profit of 9 Major Japan Pharmas
February 28, 2014
- Nipro Opens Sales Subsidiary in Sweden
February 28, 2014
- Fujifilm Sets Up Chinese Subsidiary for Regenerative Medicine Business, Eyeing Provision of Epidermis Culturing Services by 2015
February 28, 2014
- All DPP-4 Inhibitors to Undergo Major Price Reductions Due to Market Expansion of Januvia/Glactiv; Re-pricing Could Affect SGLT-2 Inhibitors as Well
February 28, 2014
- 72 Drug Makers Provided 483 Billion Yen in Funding to Medical and Research Institutions in FY2012
February 27, 2014
- Quintiles to Increase Contract Sales Reps in Japan: Global Commercial Head Evangelista
February 26, 2014
ページ
In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…